Millendo Therapeutics, Inc. 4,166,667 Shares Common Stock ($0.001 par value) Underwriting AgreementMillendo Therapeutics, Inc. • December 5th, 2019 • Pharmaceutical preparations • New York
Company FiledDecember 5th, 2019 Industry Jurisdiction
Genocea Biosciences, Inc. [·] Shares of Common Stock ($0.001 par value per share) Underwriting AgreementGenocea Biosciences, Inc. • June 18th, 2019 • Biological products, (no disgnostic substances) • New York
Company FiledJune 18th, 2019 Industry Jurisdiction
Underwriting AgreementApplied Therapeutics Inc. • April 29th, 2019 • Pharmaceutical preparations • New York
Company FiledApril 29th, 2019 Industry JurisdictionThis press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting AgreementDermira, Inc. • March 20th, 2019 • Pharmaceutical preparations • New York
Company FiledMarch 20th, 2019 Industry JurisdictionDermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth on Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth on Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to
Proteostasis Therapeutics, Inc. 11,000,000 Shares Common Stock (par value $0.001 per share) Underwriting AgreementProteostasis Therapeutics, Inc. • October 24th, 2018 • Pharmaceutical preparations • New York
Company FiledOctober 24th, 2018 Industry JurisdictionProteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 11,000,000 shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,650,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requi
Reata Pharmaceuticals, Inc. 3,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementReata Pharmaceuticals Inc • July 26th, 2018 • Pharmaceutical preparations • New York
Company FiledJuly 26th, 2018 Industry JurisdictionReata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated (together, the “Representatives”) are acting as representatives, 3,000,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 450,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the
Translate Bio, Inc. Shares Common Stock ($0.001 par value per share) Underwriting AgreementTranslate Bio, Inc. • June 12th, 2018 • Biological products, (no disgnostic substances) • New York
Company FiledJune 12th, 2018 Industry JurisdictionThis press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
BrightView Holdings, Inc. [●] Shares Common Stock ($0.01 par value) Underwriting AgreementBrightView Holdings, Inc. • June 11th, 2018 • Agricultural services • New York
Company FiledJune 11th, 2018 Industry JurisdictionBrightView Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of common stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 21 hereof.
Apellis Pharmaceuticals, Inc. Shares Common Stock ($0.0001 par value per share) Underwriting AgreementApellis Pharmaceuticals, Inc. • April 16th, 2018 • Pharmaceutical preparations • New York
Company FiledApril 16th, 2018 Industry JurisdictionApellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
Proteostasis Therapeutics, Inc. 8,000,000 Shares Common Stock (par value $0.001 per share) Underwriting AgreementProteostasis Therapeutics, Inc. • December 15th, 2017 • Pharmaceutical preparations • New York
Company FiledDecember 15th, 2017 Industry JurisdictionProteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 8,000,000 shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,200,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir
Apellis Pharmaceuticals, Inc. Shares Common Stock ($0.0001 par value per share) Underwriting AgreementApellis Pharmaceuticals, Inc. • October 20th, 2017 • Pharmaceutical preparations • New York
Company FiledOctober 20th, 2017 Industry JurisdictionApellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural
3,250,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementReata Pharmaceuticals Inc • July 28th, 2017 • Pharmaceutical preparations • New York
Company FiledJuly 28th, 2017 Industry JurisdictionReata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated (together, the “Representatives”) are acting as representatives, 3,250,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 487,500 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the
Gardner Denver Holdings, Inc. 41,300,000 Shares Common Stock ($0.01 par value) Underwriting AgreementGardner Denver Holdings, Inc. • May 3rd, 2017 • General industrial machinery & equipment • New York
Company FiledMay 3rd, 2017 Industry JurisdictionGardner Denver Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 41,300,000 shares of common stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 6,195,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 21 hereof.
Calithera Biosciences, Inc. 6,830,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementCalithera Biosciences, Inc. • March 22nd, 2017 • Pharmaceutical preparations • New York
Company FiledMarch 22nd, 2017 Industry JurisdictionCalithera Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, 6,830,000 shares of common stock, $ 0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,024,500 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriters shall mean either the singular or plural as the context requires. Certain terms use
Dermira, Inc. 5,000,000 Shares Common Stock ($0.001 par value) Underwriting AgreementDermira, Inc. • March 2nd, 2017 • Pharmaceutical preparations • New York
Company FiledMarch 2nd, 2017 Industry JurisdictionDermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth on Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth on Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representative as used herein shall mean you, as Underwriters, and the term Underwriters shall mean either the singular or
Proteostasis Therapeutics, Inc. [●] Shares Common Stock (par value $0.001 per share) Underwriting AgreementProteostasis Therapeutics, Inc. • August 31st, 2016 • Pharmaceutical preparations • New York
Company FiledAugust 31st, 2016 Industry JurisdictionProteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain
Oncobiologics, Inc. [________] Shares1 Common Stock ($0.01 par value) Underwriting AgreementOncobiologics, Inc. • April 27th, 2016 • Biological products, (no disgnostic substances) • New York
Company FiledApril 27th, 2016 Industry Jurisdiction
Epizyme, Inc. 13,333,334 Shares Common Stock ($0.0001 par value) Underwriting AgreementEpizyme, Inc. • January 7th, 2016 • Pharmaceutical preparations • New York
Company FiledJanuary 7th, 2016 Industry JurisdictionEpizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 13,333,334 shares of its common stock, $0.0001 par value (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 2,000,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used her
First Data Corporation 160,000,000 Shares Class A Common Stock ($0.01 par value) Underwriting AgreementFirst Data Corp • October 1st, 2015 • Services-business services, nec • New York
Company FiledOctober 1st, 2015 Industry JurisdictionFirst Data Corporation, a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 160,000,000 shares of Class A common stock, $0.01 par value (“Class A Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 24,000,000 additional shares of Class A Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 22 hereof.
Genocea Biosciences, Inc. 3,850,000 Shares Common Stock ($0.001 par value) Underwriting AgreementGenocea Biosciences, Inc. • July 30th, 2015 • Biological products, (no disgnostic substances) • New York
Company FiledJuly 30th, 2015 Industry JurisdictionGenocea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 3,850,000 shares of common stock, $0.001 par value (“Common Stock”), of the Company (such shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 577,500 additional shares of Common Stock, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir
Catabasis Pharmaceuticals, Inc. Shares Common Stock ($0.001 par value per share) Underwriting AgreementCatabasis Pharmaceuticals Inc • June 11th, 2015 • Pharmaceutical preparations • New York
Company FiledJune 11th, 2015 Industry JurisdictionCatabasis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plura
Epizyme, Inc. 6,000,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementEpizyme, Inc. • March 18th, 2015 • Pharmaceutical preparations • New York
Company FiledMarch 18th, 2015 Industry JurisdictionEpizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 6,000,000 shares of its common stock, $0.0001 par value (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 900,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used herein
Genocea Biosciences, Inc. 5,454,545 Shares Common Stock ($0.001 par value) Underwriting AgreementGenocea Biosciences, Inc. • March 12th, 2015 • Biological products, (no disgnostic substances) • New York
Company FiledMarch 12th, 2015 Industry JurisdictionGenocea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 5,454,545 shares of common stock, $0.001 par value (“Common Stock”), of the Company (such shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 818,181 additional shares of Common Stock, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir
AltheaDx, Inc. [—] Shares Common Stock ($0.0001 par value) Underwriting AgreementAltheaDx, Inc. • January 23rd, 2015 • Services-medical laboratories • New York
Company FiledJanuary 23rd, 2015 Industry JurisdictionAltheaDx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Jefferies LLC (the “Representatives”) are acting as representatives, [—] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [—] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singu
AltheaDx, Inc. [—] Shares Common Stock ($0.0001 par value) Underwriting AgreementAltheaDx, Inc. • December 23rd, 2014 • Services-medical laboratories • New York
Company FiledDecember 23rd, 2014 Industry JurisdictionAltheaDx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Jefferies LLC (the “Representatives”) are acting as representatives, [—] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [—] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singu
Flexion Therapeutics, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementFlexion Therapeutics Inc • December 8th, 2014 • Pharmaceutical preparations • New York
Company FiledDecember 8th, 2014 Industry JurisdictionFlexion Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the
CONTINENTAL BUILDING PRODUCTS, INC. 7,000,000 Shares Common Stock ($0.001 par value) Underwriting AgreementContinental Building Products, Inc. • November 17th, 2014 • Concrete, gypsum & plaster products • New York
Company FiledNovember 17th, 2014 Industry JurisdictionThis is to confirm the agreement among the Selling Stockholder, the Company and the Underwriters concerning the purchase of the Securities from the Selling Stockholder by the Underwriters.
Heritage Insurance Holdings, Inc. [__] Shares Common Stock ($ 0.0001 par value) Underwriting AgreementHeritage Insurance Holdings, LLC • May 16th, 2014 • Fire, marine & casualty insurance • New York
Company FiledMay 16th, 2014 Industry JurisdictionHeritage Insurance Holdings, Inc., a corporation organized under the laws of Delaware (together with its predecessor Heritage Insurance Holdings, LLC, a Delaware limited liability company, the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [__] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [__] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwrit
GrubHub Inc. Shares Common Stock ($0.0001 par value) Form of Underwriting AgreementGrubHub Inc. • March 24th, 2014 • Services-business services, nec • New York
Company FiledMarch 24th, 2014 Industry JurisdictionGrubHub Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are acting as the representatives (the “Representatives”), [—] shares of common stock, $0.0001 par value per share (“Common Stock”), of the Company, and the persons named in Schedule II hereto (the “Selling Stockholders”) propose, subject to the terms and conditions stated herein, to sell to the several Underwriters [—] shares of Common Stock (said shares to be issued and sold by the Company and shares to be sold by the Selling Stockholders collectively being hereinafter called the “Underwritten Securities”). The Company [and the Selling Stockholders] named in Schedule II hereto also propose to grant to the Underwriters an option to purchase up to [—] and [—], respectively, additional shares of Common Stock to cover over-allotments,
GrubHub Inc. Shares Common Stock ($0.0001 par value) Form of Underwriting AgreementGrubHub Inc. • March 20th, 2014 • Services-business services, nec • New York
Company FiledMarch 20th, 2014 Industry JurisdictionGrubHub Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are acting as the representatives (the “Representatives”), [—] shares of common stock, $0.0001 par value per share (“Common Stock”), of the Company, and the persons named in Schedule II hereto (the “Selling Stockholders”) propose, subject to the terms and conditions stated herein, to sell to the several Underwriters [—] shares of Common Stock (said shares to be issued and sold by the Company and shares to be sold by the Selling Stockholders collectively being hereinafter called the “Underwritten Securities”). The Company [and the Selling Stockholders] named in Schedule II hereto also propose to grant to the Underwriters an option to purchase up to [—] and [—], respectively, additional shares of Common Stock to cover over-allotments,
CONTINENTAL BUILDING PRODUCTS, INC. [13,236,000] Shares Common Stock ($0.001 par value) Form of Underwriting AgreementContinental Building Products, Inc. • January 31st, 2014 • Concrete, gypsum & plaster products • New York
Company FiledJanuary 31st, 2014 Industry JurisdictionContinental Building Products, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [11,765,000] shares of common stock, $0.001 par value (“Common Stock”) of the Company and LSF8 Gypsum Holdings, L.P., a Delaware limited partnership (the “Selling Stockholder”), proposes to sell to the several Underwriters [1,471,000] shares of Common Stock (said shares to be issued and sold by the Company and said shares to be sold by the Selling Stockholder collectively being hereinafter called the “Underwritten Securities”). The Selling Stockholder also proposes to grant to the Underwriters an option to purchase up to [1,985,400] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Secur
Flexion Therapeutics, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementFlexion Therapeutics Inc • January 29th, 2014 • Pharmaceutical preparations • New York
Company FiledJanuary 29th, 2014 Industry JurisdictionFlexion Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the
Acceleron Pharma Inc. [·] Shares (1) Common Stock ($0.001 par value) Underwriting AgreementAcceleron Pharma Inc • January 21st, 2014 • Biological products, (no disgnostic substances) • New York
Company FiledJanuary 21st, 2014 Industry JurisdictionCitigroup Global Markets Inc. Leerink Partners LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
Sophiris Bio Inc. [ ] Common Shares (no par value) Underwriting AgreementSophiris Bio Inc. • August 7th, 2013 • Pharmaceutical preparations • New York
Company FiledAugust 7th, 2013 Industry JurisdictionSophiris Bio Inc., a corporation organized under the laws of British Columbia, Canada (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ — ] of the Company’s common shares, no par value (“Common Shares”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ — ] additional Common Shares to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Ce
Eaton Vance Corp. Underwriting AgreementEaton Vance Corp • June 17th, 2013 • Investment advice • New York
Company FiledJune 17th, 2013 Industry JurisdictionEaton Vance Corp., a corporation organized under the laws of Maryland (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its securities identified in Schedule I hereto (the “Securities”), to be issued under an indenture (the “Indenture”) dated as of October 2, 2007, between the Company and Wilmington Trust, National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives, as used herein, shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein